NGS isn’t “next gen” anymore. The core sequencing instrument market is dominated by a small number of established platform vendors, and that’s not changing. If your growth strategy still depends on competing for that instrument-level attention, you’re fighting a battle that was decided years ago.
But NGS as a whole is still genuinely growing, just not where it used to. Clinical sequencing for rare disease, oncology, and pharmacogenomics is becoming routine rather than exceptional. Diagnostic labs are upgrading to clinical-grade systems. Falling per-sample costs are pulling sequencing into smaller, decentralized labs that couldn’t previously afford it. And underneath all of that, sample prep and library prep remain a high-recurring-revenue layer tied directly to sequencing volume, independent of which instrument the lab actually runs.
That’s the layer a reagent or kit company should be fighting for.
Why “compatible with NGS” stopped working as a pitch years ago
A library prep kit that solves a real, expensive problem (failed runs from low-input or degraded samples, wasted reagents, delayed clinical turnaround) is a sales conversation a diagnostic lab director actually wants to have. A kit that’s just “compatible with next-generation sequencing” sounds exactly like every other kit on the shelf next to it.
PSG Life Sciences works across the genomics technologies market every day: sample extraction and purification, library preparation kits and automation, RNA/DNA sample QC and analysis, and the molecular biology reagents this entire workflow depends on. We know the difference between a generic NGS pitch and one that actually lands with a clinical lab director under deadline pressure.
Where PSG Life Sciences fits
Still positioning your kit as generically “NGS-compatible”? Our Start solution rebuilds your messaging around the specific sample type, application, and failure mode your product actually solves.
Have research-stage traction but need to break into clinical diagnostic accounts? Our Grow solution builds the CRM segmentation that separates research-stage from clinical-diagnostic-stage leads, because a clinical account’s reorder volume over time typically dwarfs a one-time research sale, and deserves a different sales motion from day one.
Need to track reorder rate and failed-run complaints as upsell signals? HubSpot Life Sciences Pro configures the CRM to surface this automatically, instead of leaving it buried in support tickets no one connects back to sales.
What we actually build for NGS sample prep and library prep companies
- Positioning built around named sample types and failure modes (low-input recovery, degraded tissue, repeat-run reduction) instead of generic sequencing compatibility claims
- Clinical diagnostic account prioritization, since this segment generates disproportionate recurring revenue relative to its initial deal size
- CRM segmentation by research-stage vs. clinical-diagnostic-stage, with reorder rate and volume trend tracked as the primary health signal, not just new-deal count
- Quality control and upsell tracking, surfacing failed-run complaints as the signal they actually are
- Distributor strategy where it extends reach into decentralized labs more efficiently than direct sales
A direct question worth asking yourself
Right now, can you tell which of your accounts are clinical diagnostic labs generating steady reorder volume versus one-time research purchases, or does your CRM treat every NGS lead the same?
Ready to be a workflow solver, not just a me-too technology?
PSG Life Sciences is a HubSpot Gold partner and fractional commercialization firm working exclusively with biotech, life science, and diagnostic product companies, including the genomics and sequencing workflow technologies this market runs on. We build the positioning and CRM systems described above as implemented client work, not theory.